Clinical Trial: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Brief Summary: The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Detailed Summary:
Sponsor: XBiotech, Inc.

Current Primary Outcome: Change in Physician's Wound Assessment & Patient's Global Assessment [ Time Frame: 28 days ]

Original Primary Outcome: Change in Physician's Global Assessment [ Time Frame: 28 days ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: XBiotech, Inc.

Dates:
Date Received: October 15, 2013
Date Started: January 2014
Date Completion:
Last Updated: January 23, 2017
Last Verified: January 2017